Journal
GASTROENTEROLOGY
Volume 156, Issue 6, Pages 1717-1730Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2019.01.042
Keywords
VCTE; NASH; Noninvasive; Biomarker
Categories
Funding
- Echosens
- National Institute of Health Research (NIHR) Birmingham Biomedical Research Centre (BRC)
- NIHR Oxford BRC
- NIHR Nottingham BRC
- National Institute for Health Research Birmingham Biomedical Research Centre [BRC-1215-20009]
Ask authors/readers for more resources
BACKGROUND & AIMS: We estimated the accuracy of FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and fibrosis in patients with suspected nonalcoholic liver disease (NAFLD). METHODS: We collected data from 450 consecutive adults who underwent liver biopsy analysis for suspected NAFLD at 7 centers in the United Kingdom from March 2014 through January 2017. FibroScan examinations with M or XL probe were completed within the 2 weeks of the biopsy analysis (404 had a valid examination). The biopsies were scored by 2 blinded expert pathologists according to nonalcoholic steatohepatitis clinical research network criteria. Diagnostic accuracy was estimated using the area under the receiver operating characteristic curves (AUROCs) for the categories of steatosis and fibrosis. We assessed effects of disease prevalence on positive and negative predictive values. For LSM, the effects of histological parameters and probe type were appraised using multivariable analysis. RESULTS: Using biopsy analysis as the reference standard, we found that CAP identified patients with steatosis with an AUROC of 0.87 (95% confidence interval [CI] 0.82-0.92) for S >= S1, 0.77 (95% CI 0.71-0.82) for S >= S2, and 0.70 (95% CI 0.64-0.75) for S >= S3. Youden cutoff values for S >= S1, S >= S2, and S >= S3 were 302 dB/m, 331 dB/m, and 337 dB/m, respectively. LSM identified patients with fibrosis with AUROCs of 0.77 (95% CI 0.72-0.82) for F >= F2, 0.80 (95% CI 0.75-0.84) for F >= F3, and 0.89 (95% CI 0.84-0.93) for F >= F4. Youden cutoff values for F >= F2, F >= F3, and F >= F4 were 8.2 kPa, 9.7 kPa, and 13.6 kPa, respectively. Applying the optimal cutoff values, determined from this cohort, to populations of lower fibrosis prevalence increased negative predictive values and reduced positive predictive values. Multivariable analysis found that the only parameter that significantly affected LSMs was fibrosis stage q(P < 10(-16)); we found no association with steatosis or probe type. CONCLUSIONS: In a prospective analysis of patients with NAFLD, we found CAP and LSM by FibroScan to assess liver steatosis and fibrosis, respectively, with AUROC values ranging from 0.70 to 0.89. Probe type and steatosis did not affect LSM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available